| REVIEW ARTICLE |
|
| Year : 2021 | Volume
: 26
| Issue : 1 | Page : 63 |
|
|
Anticoagulation therapy in COVID-19 patients with chronic kidney disease
Mohammad Ali Shafiee1, Sayyideh Forough Hosseini1, Mojgan Mortazavi2, Anahita Emami1, Mahtab Mojtahed Zadeh1, Sanaz Moradi1, Pouyan Shaker1
1 Department of Medicine, Division of General Internal Medicine, Toronto General Hospital, Toronto, Canada
2 Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Correspondence Address:
Dr. Mohammad Ali Shafiee
Division of General Internal Medicine. Department of Medicine, University of Toronto, Royal College Mentor, Toronto, Ontario, Canada. Department of Medicine, University of Toronto, Toronto General Hospital, 200 Elizabeth Street, 14 EN-208 Toronto, ON, M5G 2C4
Canada
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jrms.JRMS_875_20
|
|
|
Coagulopathy and derangements in the coagulation parameters are significant features of COVID-19 infection, which increases the risk of disseminated intravascular coagulation, thrombosis, and hemorrhage in these patients, resulting in increased morbidity and mortality. In times of COVID-19, special consideration should be given to patients with concurrent chronic kidney disease (CKD) and COVID-19 (CKD/COVID-19 patients) as renal dysfunction increases their risk of thrombosis and hemorrhage, and falsely affects some of the coagulation factors, which are currently utilized to assess thrombosis risk in patients with COVID-19. Hence, we believe extra attention should be given to determining the risk of thrombosis and bleeding and optimizing the timing and dosage of anticoagulant therapy in this unique population of patients. CKD/COVID-19 patients are considered a high-risk population for thrombotic events and hemorrhage. Furthermore, effects of renal function on paraclinical and clinical data should be considered during the evaluation and interpretation of thrombosis risk stratification. Individualized evaluation of clinical status and kidney function is necessary to determine the best approach and management for anticoagulant therapy, whereas there is a lack of studies about the population of CKD/COVID-19 patients who need anticoagulant therapy now.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
